Genetic Mutation Impairs Immunity in Candidiasis and Mycobacteriosis
By LabMedica International staff writers Posted on 02 Aug 2015 |
Human inborn errors of immunity mediated by the cytokines interleukin-17A/F (IL-17A/F) underlie mucocutaneous candidiasis, whereas inborn errors of interferon-γ (IFN-γ) immunity underlie mycobacterial disease.
These inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis (CMC), which is characterized by chronic or recurrent infections of the skin, nails, and oral and genital mucosae by Candida albicans. The inborn errors of human IFN-γ immunity underlie Mendelian susceptibility to mycobacterial disease (MSMD), a rare congenital disorder characterized by susceptibility to infections by poorly virulent intracellular pathogens such as non-tuberculosis Mycobacterium.
An international team of scientists led by those at Hiroshima University (Japan) and the Rockefeller University (New York, NY, USA) identified bi-allelic mutations in RAR-Related Orphan Receptor C (RORC), which encoded RORγ and RORγT, in seven patients from three families of diverse ethnic origins, with an unusual combination of candidiasis and mycobacteriosis. RORγT is a well-known key transcription factor of Th17 cells, which produce IL-17 and IL-22.
The team used a variety of techniques including genome-wide linkage analysis with Genome-wide Human Mapping arrays (Affymetrix; Santa Clara, CA, USA); whole-exome sequencing where genomic DNA extracted from the patients’ blood cells was sheared with a Covaris S2 Ultrasonicator (Covaris; Woburn, MA, USA); and quantitative polymerase chain reaction (qPCR) on extracted ribonucleic acid (RNA) was performed with the Light Cycler 480 Probes Master mix (Roche; Basel, Switzerland).
Severe infection episodes associated with mycobacteria were observed in patients with an unexpected phenotype compared to that observed in previous studies on Rorc-/- mice. To explain this unexpected phenotype, the scientists focused on IFN-γ immunity and identified pathological mechanisms underlying host susceptibility to mycobacteria. Leukocytes from RORC-/- patients showed impaired IFN-γ production in response to a mycobacterial challenge, and this defect is attributable to the functional impairment of γδT cells, CD4+CCR6+CXCR3+ ab Th1* cells, or both. These findings also suggested that IFN-g treatment may be beneficial for RORC-/- patients.
The authors concluded that their results demonstrate that human RORC play a surprising dual role in host defense. These findings are clinically, immunologically, and genetically robust, as they were consistent in seven patients, from three ethnic groups, homozygous for three different RORC mutations that are loss-of-function for both isoforms. Human RORC is essential not only for the development of IL-17A/F-producing lymphocytes protecting the mucocutaneous barriers against Candida, but also for the activation of IFN-γ-producing T cells, and for systemic protection against Mycobacterium. The study was published on July 9, 2015, in the journal Science.
Related Links:
Hiroshima University
Rockefeller University
Covaris
These inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis (CMC), which is characterized by chronic or recurrent infections of the skin, nails, and oral and genital mucosae by Candida albicans. The inborn errors of human IFN-γ immunity underlie Mendelian susceptibility to mycobacterial disease (MSMD), a rare congenital disorder characterized by susceptibility to infections by poorly virulent intracellular pathogens such as non-tuberculosis Mycobacterium.
An international team of scientists led by those at Hiroshima University (Japan) and the Rockefeller University (New York, NY, USA) identified bi-allelic mutations in RAR-Related Orphan Receptor C (RORC), which encoded RORγ and RORγT, in seven patients from three families of diverse ethnic origins, with an unusual combination of candidiasis and mycobacteriosis. RORγT is a well-known key transcription factor of Th17 cells, which produce IL-17 and IL-22.
The team used a variety of techniques including genome-wide linkage analysis with Genome-wide Human Mapping arrays (Affymetrix; Santa Clara, CA, USA); whole-exome sequencing where genomic DNA extracted from the patients’ blood cells was sheared with a Covaris S2 Ultrasonicator (Covaris; Woburn, MA, USA); and quantitative polymerase chain reaction (qPCR) on extracted ribonucleic acid (RNA) was performed with the Light Cycler 480 Probes Master mix (Roche; Basel, Switzerland).
Severe infection episodes associated with mycobacteria were observed in patients with an unexpected phenotype compared to that observed in previous studies on Rorc-/- mice. To explain this unexpected phenotype, the scientists focused on IFN-γ immunity and identified pathological mechanisms underlying host susceptibility to mycobacteria. Leukocytes from RORC-/- patients showed impaired IFN-γ production in response to a mycobacterial challenge, and this defect is attributable to the functional impairment of γδT cells, CD4+CCR6+CXCR3+ ab Th1* cells, or both. These findings also suggested that IFN-g treatment may be beneficial for RORC-/- patients.
The authors concluded that their results demonstrate that human RORC play a surprising dual role in host defense. These findings are clinically, immunologically, and genetically robust, as they were consistent in seven patients, from three ethnic groups, homozygous for three different RORC mutations that are loss-of-function for both isoforms. Human RORC is essential not only for the development of IL-17A/F-producing lymphocytes protecting the mucocutaneous barriers against Candida, but also for the activation of IFN-γ-producing T cells, and for systemic protection against Mycobacterium. The study was published on July 9, 2015, in the journal Science.
Related Links:
Hiroshima University
Rockefeller University
Covaris
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form